694 related articles for article (PubMed ID: 17882280)
21. [Chronic myeloproliferative disorders. The new WHO classification].
Thiele J; Kvasnicka HM
Pathologe; 2001 Nov; 22(6):429-43. PubMed ID: 11766643
[TBL] [Abstract][Full Text] [Related]
22. [Research progress of myeloproliferative neoplasms].
He HJ; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):278-84. PubMed ID: 25687088
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.
Kaushansky K
Cytokine Growth Factor Rev; 2006 Dec; 17(6):423-30. PubMed ID: 17055768
[TBL] [Abstract][Full Text] [Related]
24. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment.
Tefferi A; Barbui T
Mayo Clin Proc; 2005 Sep; 80(9):1220-32. PubMed ID: 16178503
[TBL] [Abstract][Full Text] [Related]
25. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
26. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
27. Pathology consultation on myeloproliferative neoplasms.
Schmidt AE; Oh ST;
Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
[TBL] [Abstract][Full Text] [Related]
28. Oncogenes in myeloproliferative disorders.
Tefferi A; Gilliland DG
Cell Cycle; 2007 Mar; 6(5):550-66. PubMed ID: 17351342
[TBL] [Abstract][Full Text] [Related]
29. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
Bacher U; Haferlach T; Kern W; Hiddemann W; Schnittger S; Schoch C
Ann Hematol; 2005 Apr; 84(4):250-7. PubMed ID: 15692838
[TBL] [Abstract][Full Text] [Related]
30. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
31. [Classification of myeloid leukemias].
Kuriyama K
Nihon Rinsho; 2009 Oct; 67(10):1853-62. PubMed ID: 19860179
[TBL] [Abstract][Full Text] [Related]
32. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
33. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
34. Update from the latest WHO classification of MPNs: a user's manual.
Passamonti F; Maffioli M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):534-542. PubMed ID: 27913526
[TBL] [Abstract][Full Text] [Related]
35. BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment.
Vakil E; Tefferi A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S37-45. PubMed ID: 22035746
[TBL] [Abstract][Full Text] [Related]
36. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
37. Atypical myeloproliferative disorders in adults.
Zachée P
Transfus Apher Sci; 2011 Apr; 44(2):211-21. PubMed ID: 21402312
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.
Thiele J; Kvasnicka HM; Orazi A
Semin Hematol; 2005 Oct; 42(4):184-95. PubMed ID: 16210032
[TBL] [Abstract][Full Text] [Related]
39. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates.
Geyer JT; Orazi A
Int J Lab Hematol; 2016 May; 38 Suppl 1():12-9. PubMed ID: 27161873
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Tefferi A; Levine RL; Kantarjian H
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]